Cargando…

Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)

Detalles Bibliográficos
Autores principales:	Clark, Joseph I, Morse, Michael A, Wong, Michael KK, McDermott, David F, Kaufman, Howard L, Daniels, Gregory A, Perritt, Jessica C, Hua, Hong, Aung, Sandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649459/ http://dx.doi.org/10.1186/2051-1426-3-S2-P225

Ejemplares similares

Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2
por: Wong, Michael KK, et al.
Publicado: (2015)

Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2
por: Kaufman, Howard L, et al.
Publicado: (2014)

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
por: Buchbinder, Elizabeth I., et al.
Publicado: (2016)

The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)
por: Kaufman, Howard L., et al.
Publicado: (2014)

High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates
por: Wong, Michael K, et al.
Publicado: (2013)

Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes
por: Wong, Michael K, et al.
Publicado: (2014)

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM(SM) registry
por: Fishman, M., et al.
Publicado: (2019)

Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma
por: Chandar, Ashwin, et al.
Publicado: (2015)

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
por: Buchbinder, Elizabeth I., et al.
Publicado: (2019)

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
por: Alva, Ajjai, et al.
Publicado: (2016)

Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM(SM)
por: Clark, Joseph I., et al.
Publicado: (2016)

The role of surgery following incomplete response to high-dose IL-2 (HD IL-2)
por: Hughes, Tasha, et al.
Publicado: (2013)

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM(SM) registry
por: Curti, Brendan, et al.
Publicado: (2017)

Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in patients with metastatic melanoma (proclivity 02)
por: Patel, Sapna, et al.
Publicado: (2014)

Clinical benefit of high dose IL-2 (HD IL-2) therapy: evidence for improved overall survival in patients with stable disease
por: Hughes, Tasha, et al.
Publicado: (2013)

Complete metastasectomy after high-dose interleukin-2 (HD IL-2) therapy for melanoma
por: Chu, Melinda, et al.
Publicado: (2015)

Associations of Fc gamma receptor (FcgR2a, FcgR3a and FcgR2c) genotype with outcome in metastatic renal cell carcinoma (mRCC) patients receiving high dose interleukin 2 (HD-IL2)
por: Erbe, Amy K, et al.
Publicado: (2015)

A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (proclivity 01)
por: Clark, Joseph, et al.
Publicado: (2014)

High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases
por: Chu, Melinda B., et al.
Publicado: (2013)

Durability of Complete Response to Intralesional Interleukin-2 for In-Transit Melanoma
por: Khoury, Sami, et al.
Publicado: (2021)

Interleukin 18 (IL-18) and IL-3 in Extracellular Vesicles: Biomarkers for Durable Elite Control of HIV-1
por: Poveda, Eva, et al.
Publicado: (2023)

High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma
por: Silk, Ann W., et al.
Publicado: (2020)

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute
por: Davar, Diwakar, et al.
Publicado: (2017)

High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection
por: Chow, Shien, et al.
Publicado: (2014)

A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma
por: Silk, Ann W., et al.
Publicado: (2023)

Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
por: Ribas, Antoni, et al.
Publicado: (2009)

HD-SiO(2)/SiO(2) Sol@PDMS Superhydrophobic Coating with Good Durability and Anti-Corrosion for Protection of Al Sheets
por: Xia, Ruohan, et al.
Publicado: (2023)

Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma
por: Kaufman, Howard L, et al.
Publicado: (2009)

Stretchable and durable HD-sEMG electrodes for accurate recognition of swallowing activities on complex epidermal surfaces
por: Zhang, Ding, et al.
Publicado: (2023)

Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case series
por: Nikanjam, Mina, et al.
Publicado: (2022)

Effects of Hd2 in the presence of the photoperiod-insensitive functional allele of Hd1 in rice
por: Zhang, Zhen-Hua, et al.
Publicado: (2016)

Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: A phase II study
por: Boberg, Erik, et al.
Publicado: (2020)

Correction: Stretchable and durable HD-sEMG electrodes for accurate recognition of swallowing activities on complex epidermal surfaces
por: Zhang, Ding, et al.
Publicado: (2023)

Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD
por: Ashami, Kidist, et al.
Publicado: (2018)

Reactions of H(2), HD, and D(2) with H(2)(+), HD(+), and D(2)(+): Product-Channel Branching Ratios and Simple Models
por: Merkt, Frédéric, et al.
Publicado: (2022)

Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2
por: Clark, Joseph I, et al.
Publicado: (2021)

A Batf3/Nlrp3/IL-18 Axis Promotes Natural Killer Cell IL-10 Production during Listeria monocytogenes Infection
por: Clark, Sarah E., et al.
Publicado: (2018)

Enhanced Interleukin (IL)-13 Responses in Mice Lacking IL-13 Receptor α 2
por: Wood, Nancy, et al.
Publicado: (2003)

Arabidopsis histone deacetylase HD2A and HD2B regulate seed dormancy by repressing DELAY OF GERMINATION 1
por: Han, Yongtao, et al.
Publicado: (2023)

Management of metastatic renal cell carcinoma in patients with poor prognosis
por: Bullock, Andrea, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_kc7qqsfek2nc62c1u3u5sl65qo